Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ring finger protein 222 is a predicted protein coding gene in humans (HGNC:34517), belonging to the RING finger (RNF) protein family[1][6]. Members of this family typically function as E3 ubiquitin ligases, contributing to ubiquitination of substrate proteins, which modulates cellular processes such as protein degradation, signal transduction, and transcriptional regulation[2]. RNF222 is predicted to bind metal ions, likely zinc, and to be an integral membrane protein[3][5][6]. There is no direct experimental evidence regarding the specific biological function or disease mechanism for RNF222, but genetic association data link it to Moyamoya disease 1[1]. No drugs, biomarkers, or safety profiles are characterized for RNF222, and it is not currently recognized as a therapeutic target. Its classification is based on sequence prediction and family membership rather than critical functional characterization. RNF222 should not be confused with RNF2 (Ring finger protein 2), which is a distinct protein with validated functions[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ring finger protein 222 (RNF222).